The Association of G9a Protein and the Outcome of Patients With Cervical Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2013 by Far Eastern Memorial Hospital
Sponsor:
Information provided by (Responsible Party):
Sheng-Mou Hsiao, Far Eastern Memorial Hospital
ClinicalTrials.gov Identifier:
NCT01505751
First received: December 27, 2011
Last updated: November 13, 2013
Last verified: November 2013
  Purpose

G9a protein was approved to be highly associated with recurrence of breast cancer, gastric cancer, hepatocellular cancer, prostate cancer and lung cancer. Therefore, the aim of this study was to clarify the association and G9a protein and cervical cancer by analyzing the immunohistochemical staining of G9a protein to the histopathologic specimen of cervical cancer and clinical data.


Condition
Cervical Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective

Resource links provided by NLM:


Further study details as provided by Far Eastern Memorial Hospital:

Primary Outcome Measures:
  • determine whether G9a protein is a risk factor of overall survival of patients with cervical cancer [ Time Frame: From the date of primary treatment until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 100 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • determine whether G9a protein is a risk factor of progression-free survival of patients with cervical cancer [ Time Frame: From the date of primary treatment until the date of first documented progression or last follow-up, whichever came first, assessed up to 100 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Residual pathology block after pathological exam


Estimated Enrollment: 70
Study Start Date: February 2012
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
cervical cancer

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with cervical cancer, and underwent primary treatment (surgery, radiotherapy or chemotherapy) in Far Eastern Memorial Hospital

Criteria

Inclusion Criteria:

  • cases with cervical cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01505751

Locations
Taiwan
Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital Recruiting
Banqiao, New Taipei, Taiwan, 22050
Contact: Sheng-Mou Hsiao, M.D.    +886-2-89667000 ext 1424    smhsiao2@gmail.com   
Sponsors and Collaborators
Far Eastern Memorial Hospital
  More Information

No publications provided

Responsible Party: Sheng-Mou Hsiao, Chief, Department of Obstetrics & Gynecology, Far Eastern Memorial Hospital
ClinicalTrials.gov Identifier: NCT01505751     History of Changes
Other Study ID Numbers: 100078-E
Study First Received: December 27, 2011
Last Updated: November 13, 2013
Health Authority: Taiwan: Institutional Review Board

Keywords provided by Far Eastern Memorial Hospital:
Outcome of cervical cancer

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female

ClinicalTrials.gov processed this record on September 22, 2014